FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2087619313> ?p ?o ?g. }

• W2087619313 endingPage "P07.060" @default.
• W2087619313 startingPage "P07.060" @default.
• W2087619313 abstract "Objective: To describe a case of natalizumab induced Progressive Multifocal Leukoencephalopathy (PML) in a multiple sclerosis (MS) patient that was successfully treated with CMX001 and to report the adverse events associated with its use. Background Natalizumab is an effective treatment for MS that has been associated with the risk of developing PML. CMX001 is an oral analogue of cidofovir which selectively inhibits viral DNA polymerase. Design/Methods: Retrospective clinical and laboratory evaluation of a patient with confirmed PML that was treated with CMX001. Results: 45 year old woman with MS on natalizumab 54 months diagnosed with PML on routine brain MRI. CSF revealed 783 copies/ml of JC virus. Five plasma exchanges were performed. Repeat CSF (day 8) revealed 9,511 copies/ml of JC virus. CMX001 was initiated on day 9 (200mg orally twice a week). After four doses, she experienced severe nausea, vomiting and diarrhea. The drug was held one week and restarted at 200mg twice a week. After two doses nausea, vomiting and diarrhea again became severe. Colonoscopy revealed eosinophilic colitis. She was started on mesalamine, cholestyramine and diphenoxylate/atropine. CMX001 was held one week and restarted at 150mg twice a week. Over the next three weeks she continued to have diarrhea and decreased appetite but less than at the higher dose. After six weeks on CMX001 150mg twice a week, she presented confused and had two observed seizures. Multiple electrolyte abnormalities were seen. CMX001 was discontinued and not restarted. JC virus in the CSF dropped while on CMX001 to 3133, 428, 140, and 78copies/ml at week 6, 9, 14, and 16 weeks respectively. Conclusions: CMX001 may have been effective for treatment of natalizumab induced PML but had significant gastrointestinal side effects at 200mg twice a week and may have contributed to two seizures. Disclosure: Dr. Hojnacki has received personal compensation for activities with Biogen Idec, Serono, Inc., Pfizer Inc, and Teva Neuroscience as a speaker and/or participant on scientific advisory boards. Dr. Zivadinov has received personal compensation for activities with Teva Neuroscience, Biogen Idec, EMD Serono, and Questcor Pharmaceuticals as a speaker and/or consultant. Dr. Zivadinov has received research support from Biogen Idec, Teva Neuroscience, Genzyme Corporation, Bracco, Questcor Pharmaceuticals and EMD Serono. Dr. Weinstock-Guttman has received personal compensation for activities with Acorda Therapeutics, Biogen Idec, Serono, Inc., Novartis, Pfizer Inc, Teva Neuroscience as a speaker and/or participant on an advisory board. Dr. Weinstock-Guttman has received research support from Acorda Therapeutics, Biogen Idec, Serono Inc., Novartis, Pfizer Inc, Teva Neuroscience, National Multiple Sclerosis Society, the National Institutes of Health, ITN, Teva Neuroscience, Aspreva-Roche, Acorda Therapeutics and Shire Pharmaceuticals." @default.
• W2087619313 created "2016-06-24" @default.
• W2087619313 creator A5043955065 @default.
• W2087619313 creator A5075596287 @default.
• W2087619313 creator A5079130521 @default.
• W2087619313 date "2012-04-22" @default.
• W2087619313 modified "2023-10-17" @default.
• W2087619313 title "Successful Treatment of Natalizumab Induced PML with CMX001 and the Side Effects Associated with Its Use (P07.060)" @default.
• W2087619313 doi "https://doi.org/10.1212/wnl.78.1_meetingabstracts.p07.060" @default.
• W2087619313 hasPublicationYear "2012" @default.
• W2087619313 type Work @default.
• W2087619313 sameAs 2087619313 @default.
• W2087619313 citedByCount "0" @default.
• W2087619313 crossrefType "journal-article" @default.
• W2087619313 hasAuthorship W2087619313A5043955065 @default.
• W2087619313 hasAuthorship W2087619313A5075596287 @default.
• W2087619313 hasAuthorship W2087619313A5079130521 @default.
• W2087619313 hasConcept C121608353 @default.
• W2087619313 hasConcept C126322002 @default.
• W2087619313 hasConcept C197934379 @default.
• W2087619313 hasConcept C203014093 @default.
• W2087619313 hasConcept C2778435480 @default.
• W2087619313 hasConcept C2779802037 @default.
• W2087619313 hasConcept C2780580376 @default.
• W2087619313 hasConcept C2780640218 @default.
• W2087619313 hasConcept C2780644213 @default.
• W2087619313 hasConcept C2780852908 @default.
• W2087619313 hasConcept C2781004633 @default.
• W2087619313 hasConcept C526805850 @default.
• W2087619313 hasConcept C71924100 @default.
• W2087619313 hasConcept C90924648 @default.
• W2087619313 hasConceptScore W2087619313C121608353 @default.
• W2087619313 hasConceptScore W2087619313C126322002 @default.
• W2087619313 hasConceptScore W2087619313C197934379 @default.
• W2087619313 hasConceptScore W2087619313C203014093 @default.
• W2087619313 hasConceptScore W2087619313C2778435480 @default.
• W2087619313 hasConceptScore W2087619313C2779802037 @default.
• W2087619313 hasConceptScore W2087619313C2780580376 @default.
• W2087619313 hasConceptScore W2087619313C2780640218 @default.
• W2087619313 hasConceptScore W2087619313C2780644213 @default.
• W2087619313 hasConceptScore W2087619313C2780852908 @default.
• W2087619313 hasConceptScore W2087619313C2781004633 @default.
• W2087619313 hasConceptScore W2087619313C526805850 @default.
• W2087619313 hasConceptScore W2087619313C71924100 @default.
• W2087619313 hasConceptScore W2087619313C90924648 @default.
• W2087619313 hasIssue "Meeting Abstracts 1" @default.
• W2087619313 hasLocation W20876193131 @default.
• W2087619313 hasOpenAccess W2087619313 @default.
• W2087619313 hasPrimaryLocation W20876193131 @default.
• W2087619313 hasRelatedWork W1506200166 @default.
• W2087619313 hasRelatedWork W1987344542 @default.
• W2087619313 hasRelatedWork W2024253875 @default.
• W2087619313 hasRelatedWork W2039318446 @default.
• W2087619313 hasRelatedWork W2080531066 @default.
• W2087619313 hasRelatedWork W2611308912 @default.
• W2087619313 hasRelatedWork W2748952813 @default.
• W2087619313 hasRelatedWork W2780146991 @default.
• W2087619313 hasRelatedWork W2899084033 @default.
• W2087619313 hasRelatedWork W41364415 @default.
• W2087619313 hasVolume "78" @default.
• W2087619313 isParatext "false" @default.
• W2087619313 isRetracted "false" @default.
• W2087619313 magId "2087619313" @default.
• W2087619313 workType "article" @default.